Patients with heart failure with reduced ejection fraction who initiated dapagliflozin therapy in routine clinical practice demonstrated a baseline-dependent blood pressure response across office, central aortic, and 24-hour ambulatory measurements, according to prospective observational findings published in BMC Cardiovascular Disorders. Following the initiation of dapagliflozin, researchers recorded modest numerical reductions in blood pressure across all evaluated modalities. Rather than producing a uniform blood pressure-lowering effect across the cohort, the extent of reduction corresponded directly to initial levels: individuals with higher baseline values experienced larger reductions, whereas patients presenting with lower starting blood pressure exhibited minimal changes.
The research sought to address ongoing clinical concerns regarding the potential for excessive blood pressure reduction in patients with heart failure with reduced ejection fraction treated with sodium–glucose cotransporter 2 inhibitors. Such concerns have persisted particularly for individuals presenting with lower baseline blood pressure, a population for whom real-world data combining office, central, and ambulatory measurements have remained limited. To evaluate these dynamics, the prospective real-world study followed 75 patients initiating dapagliflozin, of whom 65 individuals completed the six-month follow-up period and were included in the final analysis. Blood pressure evaluations were conducted at baseline and repeated after six months of dapagliflozin therapy.
The study protocol assessed hemodynamic changes across multiple modalities, specifically incorporating office blood pressure, central aortic measurements, and 24-hour ambulatory monitoring. Researchers calculated absolute and relative blood pressure changes from baseline to the six-month assessment, evaluating associations between initial readings and subsequent changes through correlation and linear regression analyses. Multivariable ANCOVA models were constructed to adjust for baseline blood pressure, patient age, sex, diabetes status, renal function, and medication treatment modifications. In these multivariable models, baseline blood pressure remained the strongest predictor of follow-up blood pressure values, reinforcing the baseline-dependent pattern observed across clinical evaluations.
Hemodynamic safety was evaluated using predefined low blood pressure thresholds, and investigators observed no increase in the prevalence of measurements falling below these safety limits during follow-up. These observational findings offer clinical reassurance regarding the blood pressure profile following dapagliflozin initiation in real-world practice, aligning with the hemodynamic safety reported in randomized clinical trials. However, the authors noted that because the study used a single-arm observational design without a protocolized background therapy regimen, blood pressure changes should not be attributed exclusively to dapagliflozin, as the observed pattern may reflect the combined influence of baseline blood pressure, regression-to-the-mean, overall clinical stabilization, measurement variability, and non-protocolized medication adjustments.
Subject of Research: Blood pressure response to dapagliflozin in heart failure with reduced ejection fraction
Article Title: Baseline-dependent blood pressure response to dapagliflozin in real-world HFrEF: insights from office, ambulatory, and central measurements
Article References: Wierzowiecka, M., Wysocki, A., Begier-Krasińska, B., Spasenenko, I., Marcinkowska, J., & Niklas, A. (2026). Baseline-dependent blood pressure response to dapagliflozin in real-world HFrEF: insights from office, ambulatory, and central measurements. BMC Cardiovascular Disorders. https://doi.org/10.1186/s12872-026-06961-9
Image Credits: AI Generated
DOI: 10.1186/s12872-026-06961-9
Keywords: dapagliflozin, heart failure, reduced ejection fraction, blood pressure, ambulatory blood pressure, central blood pressure, hemodynamic safety, observational study, Baseline-dependent, blood, pressure, response
News Source: Ophelia Keating. (November 8, 2026). Heart Failure Study Shows Baseline Dependent Blood Pressure Changes With Dapagliflozin. Scienmag.



